Published in Fertil Steril on August 13, 2007
Physical exercise-induced hippocampal neurogenesis and antidepressant effects are mediated by the adipocyte hormone adiponectin. Proc Natl Acad Sci U S A (2014) 1.69
Adiponectin receptor signalling in the brain. Br J Pharmacol (2012) 1.28
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod (2010) 0.95
Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism (2010) 0.90
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Adiponectin multimers in maternal plasma. J Matern Fetal Neonatal Med (2008) 0.89
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab (2008) 0.89
Adiponectin and polycystic ovary syndrome. Biol Res Nurs (2010) 0.79
Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance. Eur J Endocrinol (2010) 0.77
Oligo-ovulation or anovulation and hyperandrogenemia contribute to the decreased serum adiponectin levels in normal-weight women with PCOS with obesity and insulin resistance. Fertil Steril (2009) 0.76
Prediction of metabolic syndrome in women with polycystic ovary syndrome. J Turk Ger Gynecol Assoc (2012) 0.76
Association between circulating adiponectin levels and polycystic ovarian syndrome. J Ovarian Res (2014) 0.75
The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis. Reprod Biol Endocrinol (2014) 0.75
Downregulation of adiponectin system in granulosa cells and low levels of HMW adiponectin in PCOS. J Assist Reprod Genet (2015) 0.75
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Long-term effect of the Internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care (2006) 2.85
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod (2013) 2.66
Establishment of blood glucose monitoring system using the internet. Diabetes Care (2004) 2.51
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 1.99
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls--implications for regulation of pubertal maturation. J Clin Endocrinol Metab (2009) 1.82
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
The effect of infertility medication on thyroid function in hypothyroid women who conceive. Thyroid (2007) 1.60
Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab (2006) 1.55
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J Clin Endocrinol Metab (2003) 1.47
The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab (2006) 1.46
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus. Atherosclerosis (2013) 1.37
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab (2013) 1.30
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol (2004) 1.21
Aberrant expression of growth differentiation factor-9 in oocytes of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2002) 1.21
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther (2013) 1.17
Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab (2007) 1.17
Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.17
Distinct developmental signatures of human abdominal and gluteal subcutaneous adipose tissue depots. J Clin Endocrinol Metab (2012) 1.17
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer. J Clin Oncol (2004) 1.11
Plasma triacylglycerol and HDL cholesterol concentrations confirm self-reported changes in carbohydrate and fat intakes in women in a diet intervention trial. J Nutr (2004) 1.08
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res (2007) 1.08
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Impaired fatty acid metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists. Am J Physiol Endocrinol Metab (2005) 1.07
Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J Clin Endocrinol Metab (2007) 1.07
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2008) 1.05
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab (2005) 1.00
Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985) (2010) 0.99
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
A comparison of letrozole to gonadotropins for ovulation induction, in subjects who failed to conceive with clomiphene citrate. Fertil Steril (2007) 0.98
Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep (2002) 0.98
Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. J Clin Endocrinol Metab (2005) 0.98
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Risk of surgery after use of potassium chloride for treatment of tubal heterotopic pregnancy. Obstet Gynecol (2006) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97
Fertility management for women with cancer. Cancer Treat Res (2007) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab (2008) 0.96
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab (2005) 0.95
Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation. Cancer Treat Res (2007) 0.95
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab (2010) 0.95
Future Directions in Oncofertility and Fertility Preservation: A Report from the 2011 Oncofertility Consortium Conference. J Adolesc Young Adult Oncol (2013) 0.95
Evidence for abnormal granulosa cell responsiveness to follicle-stimulating hormone in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.94
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Incretin therapies: effects beyond glycemic control. Am J Med (2009) 0.93
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol (2006) 0.93
Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants. Obesity (Silver Spring) (2010) 0.92
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism (2003) 0.92